FibroGen (FGEN) Competitors $0.33 -0.01 (-3.54%) Closing price 04:00 PM EasternExtended Trading$0.33 0.00 (0.00%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. EDIT, EXOZ, LRMR, CGEN, LYEL, NKTX, THTX, BDTX, IFRX, and ALTSShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Editas Medicine (EDIT), Exozymes (EXOZ), Larimar Therapeutics (LRMR), Compugen (CGEN), Lyell Immunopharma (LYEL), Nkarta (NKTX), Theratechnologies (THTX), Black Diamond Therapeutics (BDTX), InflaRx (IFRX), and Janone (ALTS). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Editas Medicine Exozymes Larimar Therapeutics Compugen Lyell Immunopharma Nkarta Theratechnologies Black Diamond Therapeutics InflaRx Janone FibroGen (NASDAQ:FGEN) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings. Which has more volatility & risk, FGEN or EDIT? FibroGen has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500. Do institutionals and insiders believe in FGEN or EDIT? 72.7% of FibroGen shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.1% of FibroGen shares are owned by company insiders. Comparatively, 2.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer FGEN or EDIT? In the previous week, Editas Medicine had 5 more articles in the media than FibroGen. MarketBeat recorded 13 mentions for Editas Medicine and 8 mentions for FibroGen. Editas Medicine's average media sentiment score of 0.65 beat FibroGen's score of -0.90 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Editas Medicine 5 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate FGEN or EDIT? FibroGen currently has a consensus target price of $10.00, indicating a potential upside of 2,912.05%. Editas Medicine has a consensus target price of $5.36, indicating a potential upside of 257.58%. Given FibroGen's stronger consensus rating and higher possible upside, analysts plainly believe FibroGen is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Editas Medicine 2 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.29 Is FGEN or EDIT more profitable? FibroGen has a net margin of -67.66% compared to Editas Medicine's net margin of -340.96%. FibroGen's return on equity of 0.00% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets FibroGen-67.66% N/A -36.17% Editas Medicine -340.96%-80.13%-50.99% Which has better valuation & earnings, FGEN or EDIT? Editas Medicine has higher revenue and earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$7.00M4.80-$284.23M-$0.10-3.32Editas Medicine$35.84M3.50-$153.22M-$3.04-0.49 Does the MarketBeat Community prefer FGEN or EDIT? FibroGen received 30 more outperform votes than Editas Medicine when rated by MarketBeat users. Likewise, 58.81% of users gave FibroGen an outperform vote while only 53.46% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformFibroGenOutperform Votes34758.81% Underperform Votes24341.19% Editas MedicineOutperform Votes31753.46% Underperform Votes27646.54% SummaryFibroGen beats Editas Medicine on 12 of the 19 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.55M$6.49B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-0.278.9326.5819.71Price / Sales4.80251.28391.69116.98Price / CashN/A65.8538.2534.62Price / Book-0.186.466.794.50Net Income-$284.23M$143.98M$3.23B$248.18M7 Day Performance10.70%3.02%4.03%1.14%1 Month Performance15.80%7.45%12.50%15.19%1 Year Performance-72.10%-2.42%16.73%6.55% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.4121 of 5 stars$0.33-3.5%$10.00+2,912.0%-71.3%$33.55M$7.00M-0.27570EDITEditas Medicine4.2699 of 5 stars$1.49-1.3%$5.36+260.0%-70.3%$124.73M$35.84M-0.58230Positive NewsGap UpEXOZExozymesN/A$14.90-0.9%N/AN/A$124.68MN/A0.0029Gap UpLRMRLarimar Therapeutics2.0753 of 5 stars$1.95-1.8%$19.63+909.0%-71.7%$124.53MN/A-1.6930Positive NewsCGENCompugen1.6041 of 5 stars$1.39flat$4.00+187.8%-19.0%$124.04M$27.86M69.5070News CoverageEarnings ReportAnalyst RevisionLYELLyell Immunopharma2.9698 of 5 stars$0.41-0.5%$1.00+142.1%-84.2%$122.00M$61,000.00-0.52270Positive NewsGap DownNKTXNkarta1.9798 of 5 stars$1.70-2.3%$14.67+762.7%-73.3%$120.63MN/A-0.90140Trending NewsEarnings ReportAnalyst RevisionGap UpTHTXTheratechnologiesN/A$2.61flatN/A+108.8%$120.01M$88.67M-26.10140Gap DownBDTXBlack Diamond Therapeutics3.3341 of 5 stars$2.11+8.2%$14.60+591.9%-55.7%$119.98M$70M-1.5990News CoveragePositive NewsIFRXInflaRx2.3736 of 5 stars$1.77+6.6%$8.50+380.2%+14.9%$118.83M$129,752.00-1.6460ALTSJanoneN/A$6.80flatN/AN/A$118.69M$12.53M0.00170News Coverage Related Companies and Tools Related Companies Editas Medicine Competitors Exozymes Competitors Larimar Therapeutics Competitors Compugen Competitors Lyell Immunopharma Competitors Nkarta Competitors Theratechnologies Competitors Black Diamond Therapeutics Competitors InflaRx Competitors Janone Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FGEN Stock Free FGEN Stock Alerts